Novartis AG buy stratec
Start price
30.01.19
/
50%
€75.44
Target price
04.11.21
€92.40
Performance (%)
6.04%
End price
05.11.21
€80.00
Summary
This prediction ended on 05.11.21 with a price of €80.00. With a performance of 6.04%, the BUY prediction by stratec for Novartis AG closed with a slight gain. Dividends of €14.47 are taken into consideration when calculating the performance. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novartis AG | - | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
Comments by stratec for this prediction
In the thread Novartis AG diskutieren
Novartis expects to launch at least 10 blockbusters by 2020
In-market growth drivers will be led by 15 blockbusters (annual sales of at least $1B), including predictable names such as Cosentyx, Entresto and Promacta. The company is also counting on aggressive sales ramps from breast cancer med Kisqali (Q4 sales: $60M), radiotherapy Lutathera (Q4 sales: $81M), CAR-T Kymriah (Q4 sales: $28M) and biosimilars.
It expects to launch at least 10 blockbusters by 2020, including Zolgensma, Mayzent, RTH258, Aimovig, OMB157, BYL719, SEG101 and biosimilars.
In the thread Trading Novartis AG
Die von stratec gewählte maximale Laufzeit wurde überschritten